{"editorial":{"content_id":"5ebef85e-9ba4-45cd-91f4-b509be631c67","slug":"anvisa-glp-20261029-3617cd","content_type":"news","title":"巴西Anvisa批准五款新型GLP-1注射笔，三款治糖尿病两款治肥胖","summary":"巴西国家卫生监督局10月29日批准五款新型GLP-1注射笔注册，其中三款用于糖尿病、两款用于肥胖症治疗。","body":"巴西国家卫生监督局（Anvisa）于周四（10月29日）批准了五款新型GLP-1注射笔的注册，其中三款用于治疗糖尿病，两款用于治疗肥胖症。\n\n获批产品中，Aribet（利拉鲁肽）用于糖尿病治疗，Lyrza（利拉鲁肽）和Wylovol（利拉鲁肽）用于肥胖症治疗，须配合运动与饮食调整。这三款注册均授予Farma Vision Importação e Exportação de Medicamentos Ltda，由印度Biocon公司生产。\n\nEmbeltah（司美格鲁肽）用于糖尿病治疗，注册授予Dr.Reddys Farmacêutica do Brasil Ltda，由印度OneSource Specialty公司生产；Sevema（司美格鲁肽）同样用于糖尿病治疗，注册授予Aché Laboratórios Farmacêuticos S.A，亦由印度OneSource Specialty公司生产。\n\n随着这五项注册于周四公布，Anvisa在2026年已累计批准20款注射笔。据Anvisa说明，自2025年8月启动的对司美格鲁肽和利拉鲁肽类药物的优先审查，源于卫生部为统一卫生系统（SUS）利益、在卫生经济工业综合体（Ceis）框架内提出的请求，以及国内市场供应需求，最终促成该局第12/2025号征询公告的发布。相关决议第4.244/2026号已刊登于联邦官方公报（DOU）。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","行业趋势","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-10-29T11:01:25.696Z","display_date":"2026-10-29","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-cinco-novas-canetas-de-glp-1","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-glp-20261029-3617cd","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glp-20261029-3617cd","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glp-20261029-3617cd?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glp-20261029-3617cd?view=json","last_updated":"2026-10-29T11:01:52.781Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}